Dimeric triazole-chalcone conjugate as multi-target directed β-amyloid inhibitor

Key Points

• The dimeric triazole-chalcone conjugate effectively inhibits β-amyloid formation, a key factor in neurodegeneration.
• Significant inhibition of β-amyloid was observed with a maximum reduction of 75% in laboratory tests.
• Observational analysis using in vitro models allowed us to assess the compound's multi-target capabilities against β-amyloid aggregation.
• This research supports the need for further investigation of this inhibitor in clinical settings, with potential therapeutic implications.